Clinical Trial

Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two utilizes a randomized, blinded, placebo-controlled design. Part One is divided into four stages based on age and vaccine dose levels. Part Two consists of the 2-month-old vaccine/placebo groups.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-25.
Status change: Not Yet Recruiting → Recruiting 2025-12-25
Trial Details
NCT Number NCT07203755
Lead Sponsor CanSino Biologics Inc.
Conditions Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection
Enrollment 260 participants
Start Date 2025-12-19
Primary Completion 2029-02 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2025-12-31